Clinical trial
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With…
NCT00225615 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00225615 |
|---|---|
| Title | A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels |
| Official title | A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Phenylketonurias |
| Intervention type | Drug |
| Interventions | sapropterin dihydrochloride |
| Enrollment | 100 |
| Start date | Nov 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Sep 26, 2005 |
| Last update posted | Aug 20, 2009 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: